dc.creator | Bogdanos D.P., Sakkas L.I. | en |
dc.date.accessioned | 2023-01-31T07:38:49Z | |
dc.date.available | 2023-01-31T07:38:49Z | |
dc.date.issued | 2017 | |
dc.identifier | 10.1097/BOR.0000000000000394 | |
dc.identifier.issn | 10408711 | |
dc.identifier.uri | http://hdl.handle.net/11615/71771 | |
dc.description.abstract | Purpose of review The current review discusses the pros and cons of the microbiome studies conducted in search of the association between microbiota and autoimmunity. Recent findings We focus on the role of infectome and autoinfectome as a bridge to link the findings of microbiome studies with those emerging from investigations of the role of specific viruses and antiviral responses as triggers of autoimmunity (through various mechanisms such as molecular mimicry). The 'usual suspects', such as herpetoviruses and Escherichia coli, are thoroughly discussed in light of the data emerged by the microbiome studies, using as examples specific autoimmune rheumatic diseases and inflammatory bowel diseases. Summary We conclude that the studies of the oral cavity, gastrointestinal, and urinary tract microbiome are informative but can only be useful if further explored from the infectome perspective. This means that the plethora of bacteria associated with autoimmune diseases from microbiome studies can be and must be tested experimentally. If certain bacteria are associated directly or indirectly with autoimmune diseases, specific immunological mechanisms must be identified. © 2017 Wolters Kluwer Health, Inc. All rights reserved. | en |
dc.language.iso | en | en |
dc.source | Current Opinion in Rheumatology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017268705&doi=10.1097%2fBOR.0000000000000394&partnerID=40&md5=4228a2e5a1af34d2a1abcd9c6554dc04 | |
dc.subject | autoantibody | en |
dc.subject | autoantigen | en |
dc.subject | cyclic citrullinated peptide antibody | en |
dc.subject | autoimmune disease | en |
dc.subject | autoimmunity | en |
dc.subject | autoinfectome | en |
dc.subject | Cytomegalovirus | en |
dc.subject | Epstein Barr virus | en |
dc.subject | Epstein Barr virus infection | en |
dc.subject | Escherichia coli | en |
dc.subject | human | en |
dc.subject | infection | en |
dc.subject | infectome | en |
dc.subject | inflammatory bowel disease | en |
dc.subject | intestine flora | en |
dc.subject | microbiome | en |
dc.subject | molecular mimicry | en |
dc.subject | mononucleosis | en |
dc.subject | mouth cavity | en |
dc.subject | mouth flora | en |
dc.subject | nonhuman | en |
dc.subject | priority journal | en |
dc.subject | Review | en |
dc.subject | rheumatoid arthritis | en |
dc.subject | Sjoegren syndrome | en |
dc.subject | systemic lupus erythematosus | en |
dc.subject | systemic sclerosis | en |
dc.subject | urinary tract | en |
dc.subject | autoimmune disease | en |
dc.subject | autoimmunity | en |
dc.subject | cytomegalovirus infection | en |
dc.subject | Escherichia coli infection | en |
dc.subject | immunology | en |
dc.subject | microbiology | en |
dc.subject | microflora | en |
dc.subject | virology | en |
dc.subject | virus infection | en |
dc.subject | Arthritis, Rheumatoid | en |
dc.subject | Autoimmune Diseases | en |
dc.subject | Autoimmunity | en |
dc.subject | Cytomegalovirus | en |
dc.subject | Cytomegalovirus Infections | en |
dc.subject | Epstein-Barr Virus Infections | en |
dc.subject | Escherichia coli | en |
dc.subject | Escherichia coli Infections | en |
dc.subject | Gastrointestinal Microbiome | en |
dc.subject | Herpesvirus 4, Human | en |
dc.subject | Humans | en |
dc.subject | Inflammatory Bowel Diseases | en |
dc.subject | Lupus Erythematosus, Systemic | en |
dc.subject | Microbiota | en |
dc.subject | Scleroderma, Systemic | en |
dc.subject | Sjogren's Syndrome | en |
dc.subject | Virus Diseases | en |
dc.subject | Lippincott Williams and Wilkins | en |
dc.title | From microbiome to infectome in autoimmunity | en |
dc.type | other | en |